Results 161 to 170 of about 288,395 (355)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

Antidepressant Drugs [PDF]

BMJ, 1964
openaire   +5 more sources

Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study

Clinical Pharmacology &Therapeutics, EarlyView.
Fentanyl, hydromorphone, and oxycodone are metabolized by cytochrome P450 3A4 (CYP3A4). Co‐administration with CYP3A4‐inhibiting macrolides (clarithromycin or erythromycin) may increase opioid concentrations and overdose risk, but the clinical impact of these interactions is unknown.
Tony Antoniou, Joanna Yang, David N. Juurlink, Joanne M.‐W. Ho, Muhammad Mamdani, Fangyun Wu, Mina Tadrous, Tara Gomes   +7 more
wiley   +1 more source

Faculty Opinions recommendation of Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.

, 2018
Ronald S. Duman
openalex   +2 more sources

Psilocybin shows promising results in subjects continuing to use an antidepressant [PDF]

, 2023

openalex   +1 more source

Mediation Analysis Without Sequential Ignorability: Using Baseline Covariates Interacted with Random Assignment as Instrumental Variables [PDF]

, 2011
In randomized trials, researchers are often interested in mediation analysis to understand how a treatment works, in particular how much of a treatment's effect is mediated by an intermediated variable and how much the treatment directly affects the ...
Small, Dylan S.
core  

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

Antidepressant exposure and long‐term dementia risk in a nationwide study on U.S. Veterans with major depressive disorder [PDF]

, 2023
Jaime Ramos‐Cejudo, June Corrigan, Chunlei Zheng, Kaitlin N. Swinnerton, Sean Jacobson, Jennifer La, Rebecca A. Betensky, Ricardo S. Osorio, Sharon Madanes, Nunzio Pomara, Dan V. Iosifescu, Mary T. Brophy, Nhan Do, Nathanael R. Fillmore   +13 more
openalex   +1 more source

Antidepressant Pharmacogenetics [PDF]

American Journal of Psychiatry, 2017
Ajeet B, Singh, Chad A, Bousman
openaire   +2 more sources